Skip to main content

Table 1 Causal effect estimates on hypertension via Univariable Mendelian randomization

From: Leveraging IgG N-glycosylation to infer the causality between T2D and hypertension

Exposures

SNP (N)

OR (95%CI) (P value)

MR‒Egger (P value)

Weighted median method (P value)

MR‒Egger intercept (P value)

T2D

6

1.177 (1.037–1.338) (0.012)

1.548 (0.960–2.494) (0.073)

1.142 (0.941–1.387) (0.180)

− 0.384 (0.289)

GP1

167

0.976 (0.914–1.042) (0.465)

1.054 (0.907–1.224) (0.493)

1.032 (0.929–1.146) (0.554)

− 0.061 (0.327)

GP2

39

1.113 (0.956–1.297) (0.169)

1.340 (1.005–1.789) (0.046)

1.091 (0.877–1.358) (0.434)

− 0.121 (0.141)

GP3

38

1.013 (0.851–1.206) (0.887)

1.114 (0.789–1.573) (0.539)

1.146 (0.902–1.456) (0.265)

− 0.097 (0.336)

GP4

32

1.101 (0.903–1.343) (0.341)

1.290 (0.871–1.911) (0.204)

1.064 (0.806–1.406) (0.661)

− 0.095 (0.382)

GP5

77

0.987 (0.888–1.096) (0.801)

1.208 (0.969–1.507) (0.094)

1.070 (0.912–1.256) (0.408)

− 0.150 (0.048)

GP6

25

0.954 (0.787–1.158) (0.635)

0.751 (0.479–0.177) (0.212)

0.960 (0.689–1.339) (0.812)

0.138 (0.198)

GP7

29

1.091 (0.925–1.287) (0.302)

1.284 (0.913–1.804) (0.150)

1.101 (0.861–1.408) (0.442)

− 0.109 (0.260)

GP8

16

0.941 (0.709–1.250) (0.675)

0.920 (0.518–1.633) (0.776)

0.832 (0.602–1.151) (0.267)

0.015 (0.897)

GP9

15

1.210 (0.861–1.699) (0.272)

1.037 (0.383–2.809) (0.944)

1.286 (0.859–1.926) (0.222)

0.063 (0.719)

GP10

25

0.910 (0.745–1.112) (0.356)

0.712 (0.458–1.105) (0.130)

0.965 (0.729–1.279) (0.806)

0.125 (0.298)

GP11

18

0.920 (0.732–1.155) (0.472)

0.913 (0.538–1.551) (0.737)

0.958 (0.683–1.345) (0.806)

− 0.008 (0.941)

GP12

46

0.930 (0.808–1.071) (0.316)

1.151 (0.876–1.514) (0.312)

0.934 (0.758–1.150) (0.518)

− 0.126 (0.106)

GP13

58

0.970 (0.858–1.096) (0.621)

0.987 (0.776–1.254) (0.912)

0.998 (0.827–1.203) (0.979)

0.008 (0.910)

GP14

18

0.867 (0.656–1.145) (0.314)

1.104 (0.482–2.528) (0.815)

0.774 (0.514–1.168) (0.223)

− 0.102 (0.525)

GP15

18

0.775 (0.624–0.964) (0.022)

1.128 (0.626–2.035) (0.689)

0.813 (0.774–1.324) (0.197)

− 0.184 (0.170)

GP16

26

1.038 (0.868–1.241) (0.687)

0.759 (0.461–1.250) (0.278)

1.012 (0.774–1.324) (0.930)

0.142 (0.164)

GP17

60

0.828 (0.734–0.934) (0.002)

1.091 (0.855–1.392) (0.483)

0.884 (0.734–1.064) (0.191)

− 0.162 (0.034)

GP18

12

1.099 (0.815–1.482) (0.537)

1.271 (0.551–2.934) (0.574)

1.165 (0.755–1.798) (0.490)

− 0.059 (0.751)

GP19

23

0.957 (0.793–1.154) (0.645)

1.040 (0.679–1.592) (0.857)

0.946 (0.712–1.258) (0.704)

− 0.083 (0.401)

GP20

78

0.833 (0.751–0.923) (5.155 × 10–4)

0.941 (0.725–1.223) (0.650)

0.845 (0.720–0.992) (0.040)

− 0.112 (0.283)

GP21

36

1.061 (0.910–1.236) (0.450)

1.351 (0.967–1.887) (0.078)

1.065 (0.848–1.338) (0.588)

− 0.145 (0.122)

GP22

259

0.903 (0.857–0.952) (1.690 × 10–4)

1.017 (0.856–1.207) (0.852)

0.970 (0.892–1.055) (0.481)

− 0.105 (0.238)

GP23

19

1.121 (0.883–1.424) (0.347)

1.599 (0.946–2.702) (0.080)

1.300 (0.941–1.796) (0.111)

− 0.176 (0.137)

GP24

21

1.148 (0.899–1.466) (0.270)

1.718 (0.898–3.286) (0.102)

1.062 (0.778–1.451) (0.703)

− 0.154 (0.212)

  1. The results in bold indicate that the p value is less than 0.05
  2. CI: confidence intervals; GP: glycan peak; OR: odds ratio; SE: standard error; SNP: single nucleotide polymorphism; T2D: Type 2 diabetes